Study finds proteomic risk scores for cardiovascular disease from SomaSignal® Cardio DM™ tests could support physicians in managing patient outcomes

November 17, 2022 at 8:00 AM EST

BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring whether SomaLogic’s SomaSignal® tests aid physicians in the risk stratification for cardiovascular disease of their patients. Researchers from the University of California, San Francisco (UCSF) are investigating if these physicians are more likely to prescribe high-risk patients with drugs to aid in blood glucose control, like SGLT2 inhibitors and GLP-1 receptor agonists, in better alignment with current medical guidelines.

“Through prior research we discovered that physicians using traditional risk factors are having difficulties in calculating and applying risk scores in patient management,” says SomaLogic Chief Medical Officer, Stephen Williams, M.D., Ph.D. “We conducted this new study to see if we can show that individualized proteomic cardiovascular risk assessment could play a positive role in this scenario, enabling more effective allocation of drugs and improving patient outcomes.”

The study, which was conducted by QURE Healthcare, measures the use of SomaSignal test results in clinical practice using scientifically validated patient simulations to uncover what clinical decisions practicing physicians are making with patients. The full study is expected to be published in an upcoming peer-reviewed journal.

“We conducted this independent randomized trial to determine the causal impact of a more personalized risk-stratification tool,” said John Peabody, M.D., Ph.D., a professor of epidemiology and biostatistics at UCSF and the study’s principal investigator. “A positive study provides clinicians with a better tool—and one they are more likely to use—when caring for their patients.”

“SomaSignal tests continue to improve our understanding of an individual’s unique cardiac risk. More importantly, it can guide patients’ and providers’ choices regarding both lifestyle and pharmacological interventions to reduce that risk,” said Nelson Trujillo, M.D., a board-certified cardiologist who is an investigator on the study. “As a long-time user of this test in my own clinical practice, I concur with the findings of this study on this large group of physicians. I have seen it impact my own treatment recommendations and it represents a clear move forward in medical practice.”

SomaLogic’s CardioDM test, a version of the SomaSignal cardiovascular test, is currently being used in clinically focused partnerships with healthcare providers as part of the SomaSignal Proteomics for Precision Medicine Initiative. As part of the program, launched in 2021, disease-focused randomized clinical trials are being conducted by several U.S.-based healthcare innovators in diverse therapeutic areas, including Type 2 diabetes and cardiovascular disease.

Trials were launched with initial partners: Emory University, CommonSpirit Health and UCHealth. During these trials, healthcare providers are evaluating CardioDM in their clinical practices by assessing current health state and disease risk based on a patient’s proteomic signature and determining whether to change treatment because of the new information these tests provide. Clinicians are also evaluating whether providing these uniquely personalized test results to their patients motivates them to be more adherent to care recommendations.

Additionally, SomaLogic recently provided a data pre-submission for this test to the Food and Drug Administration. CardioDM is based on 27 different protein biomarkers which can predict the 4-year risk of a cardiovascular event with the median time-to-event of about 20 months.

SomaSignal tests are developed, and their performance characteristics determined, by SomaLogic. They have neither been cleared or approved by the Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.  

About SomaLogic 
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit and follow @somalogic on Twitter.  

Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors.   Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Media Contact  
Emilia Costales  

Investor Contacts 
Marissa Bych 
Gilmartin Group LLC